Advertisements

ACC (Acetylcysteine)

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of ACC (Acetylcysteine)

Property Description
Active Ingredient Acetylcysteine (N-acetylcysteine, NAC)
Forms Effervescent tablet, Oral solution, Injectable solution, Powder packet
Pharmacological Class Mucolytic agent, Antidote (for Acetaminophen toxicity)
General Purpose Aids respiratory clearance and provides hepatoprotection
Origin Synthetic N-acetyl derivative of L-cysteine

What Type of Medicine is Acetylcysteine (ACC)?

The therapeutic agent frequently identified by the trade name ACC is Acetylcysteine, which is the internationally recognized name (INN) also widely known as N-acetylcysteine (NAC). This compound holds a critical dual pharmacological classification. It functions as a mucolytic agent to manage issues with respiratory secretions, and it is also designated as an essential antidote for specific toxic ingestions. Its essential role in acute care is recognized in clinical practice.

Chemically, Acetylcysteine is a synthetic N-acetyl derivative of the naturally occurring amino acid L-cysteine, which acts as a precursor to the key cellular antioxidant, glutathione. This synthetic modification endows the molecule with its specific therapeutic properties, allowing it to act as a sulfhydryl group donor.


Composition and Available Pharmaceutical Forms

Acetylcysteine is generally prepared as a single-component product (monotherapy). The active substance is manufactured into several high-level dosage form(s) to suit diverse delivery needs, including the popular effervescent tablets, oral solution, and sterile injectable solution. The effervescent format is a common differentiating factor, preferred by patients who experience difficulty swallowing traditional tablets.

These varied forms permit administration via the oral route, through inhalation (nebulization) for direct local effect on the airways, and via the intravenous route for rapid systemic action. Its composition requires the inclusion of either an aqueous vehicle for liquid and inhalable forms or standard solid excipients for tablets, confirming its suitability for multiple administration methods in different clinical contexts.


What is the General Purpose of Acetylcysteine?

The overall purpose of Acetylcysteine is defined by its ability to provide support in two distinct physiological areas: by improving respiratory function and by protecting vital organs. Its action as a mucolytic agent involves its ability to address the clinical problem of thick, tenacious secretions. A typical use scenario involves its application in patients managing conditions associated with abnormally thick mucus, where respiratory clearance is impaired.

Furthermore, Acetylcysteine performs its vital antidote function by enabling the rapid replenishment of the Glutathione reserves in the liver. Timely administration of Acetylcysteine is used as a strategy for preventing critical liver injury in specific cases of acute overdose. This confirms its efficacy in providing essential hepatoprotective support against severe, acute chemical stress.

Advertisements

What side effects are possible with ACC (Acetylcysteine)?

Possible side effects and safety information

Official regulatory documents classify the potential adverse reactions associated with Acetylcysteine (ACC) into specific frequency categories and system-organ classes. The most frequently documented side effects are categorized as uncommon (occurring in fewer than 1 in 100 people) and typically involve the Gastrointestinal disorders system, including nausea, vomiting, diarrhoea, and abdominal pain. Other uncommon effects involve the Nervous system (headache) and Skin and subcutaneous tissue disorders (rash, pruritus, urticaria, angioedema).

Reactions categorized as rare (ge 1/10,000 to < 1/1,000) include bronchospasm (airway tightening) and dyspnoea (difficulty breathing). Serious adverse reactions, such as anaphylactic shock and severe, life-threatening skin conditions like Stevens-Johnson syndrome (SJS) and Toxic epidermal necrolysis (TEN), are explicitly documented in regulatory warnings, though their frequency may be classified as very rare or not known.

Safety statements in official labeling highlight that certain reactions may follow specific time patterns; for instance, anaphylactoid reactions associated with intravenous administration often occur soon after the initiation of the infusion. Special cautions are noted for specific populations, including individuals with bronchial asthma, who must be closely monitored due to the inherent risk of bronchospasm. Furthermore, caution is documented for patients with a history of peptic ulcers or esophageal varices due to the potential risk of upper gastrointestinal hemorrhage. The labels also define safety restrictions, advising against co-administration with antitussive drugs to prevent the accumulation of bronchial secretions.

Advertisements

Overdose and Emergency Response

The official regulatory documents define the overdose profile of Acetylcysteine based on the potential for acute, systemic manifestations. Overdose presentations commonly include gastrointestinal effects such as vomiting and nausea, alongside signs of systemic hypersensitivity like acute flushing, rash, and pruritus.

Urgent Help-Seeking and Severe Outcomes

Regulators specify that severe or life-threatening outcomes may include hypotension, tachycardia, bronchospasm, and respiratory distress. Because serious anaphylactoid reactions have been reported, immediate medical attention is required for any severe or rapidly escalating symptoms. The official emergency response mandates the immediate discontinuation of the infusion if a serious reaction occurs, followed by the initiation of appropriate treatment for hypersensitivity, such as antihistamines or epinephrine in severe cases.

Official Management Requirements

No specific antidote is known for Acetylcysteine overdose itself. Management is restricted to symptomatic and supportive treatment. Continuous monitoring of hepatic and renal function and electrolytes is required throughout the management period. Furthermore, the total volume administered must be reduced for patients weighing less than 40 kg or those requiring fluid restriction, addressing the documented risk of fluid overload.

Advertisements

Therapeutic Uses of ACC (Acetylcysteine)

Acetylcysteine is used across two primary therapeutic domains, providing both critical intervention and supportive symptomatic management. Its application includes clinical settings that involve acute or unstable symptom patterns.

The medication is commonly used to help address the primary problem of thick, sticky, or viscid secretions in the airways, a challenge in conditions characterized by periods of heightened symptoms such as Chronic Obstructive Pulmonary Disease (COPD), chronic bronchitis, and Cystic Fibrosis. Furthermore, it is essential as an antidote for acute acetaminophen (paracetamol) overdose, a critical situation associated with systemic imbalance.

It may assist in liquefying heavy phlegm, and is utilized in the management of symptoms related to physical discomfort, supporting better day-to-day comfort for patients during symptomatic periods. In acute care, it provides crucial hepatoprotection and plays a role in managing symptoms linked to organ-specific functional stress.

“Applied across domains where additional symptomatic support is needed, this agent helps address symptom clusters that may become intense or disruptive.”


Quick Fact: Relief for Thick Mucus and Acute Toxicological Stress

The use in conditions characterized by periods of heightened symptoms helps address symptom clusters that may become intense or disruptive, assisting with maintaining functional stability and supporting the patient during difficult episodes of heightened discomfort.

Regulatory References

  1. NIH StatPearls overview
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Acetylcysteine

Official regulatory documentation defines eligibility for Acetylcysteine by establishing absolute exclusions and conditional usage rules based on patient status.


Contraindications and Absolute Exclusions

Acetylcysteine is formally contraindicated in any patient with a known hypersensitivity or a history of anaphylactoid reactions to the active substance or to any excipient component of the specific formulation.

Age and Weight Qualifications

For acute antidote use (intravenous), the drug is officially indicated for adults and pediatric patients who weigh 5 kg or greater. For standard oral mucolytic applications, the drug is generally allowed for adults and adolescents over the age of 12 years. Appropriate safety studies on the relationship of age to the effects of the drug have not been fully established for the general geriatric population.

Conditional Use and Restrictions

Use requires caution and close monitoring in patients with pre-existing conditions such as bronchial asthma (due to the risk of bronchospasm), a history of stomach ulcers, or esophageal bleeding. Caution is also advised for patients with sodium-sensitive conditions like congestive heart failure or kidney disease. For pregnant women, use is generally not recommended unless clearly needed, and caution is advised during breastfeeding as drug excretion into human milk is unknown.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Acetylcysteine’s interaction profile is officially documented by regulatory authorities, focusing on specific physicochemical constraints and pharmacodynamic effects rather than extensive metabolic interactions.

Documented Interaction Patterns

Interacting Entity/Category Official Interaction Pattern/Outcome
Nitroglycerin (Organic Nitrates) Co-administration may potentiate the vasodilatory and antiplatelet effects.
Activated Charcoal Reduces the systemic absorption and exposure of orally administered Acetylcysteine.
Certain Antibiotics Direct mixing of the solution with antibiotics (e.g., tetracyclines, cephalosporins) may cause inactivation of the antibiotic.
Metals/Rubber Solutions are physicochemically incompatible with metals (iron, copper, nickel) and rubber, requiring restrictions on materials used for administration.

Administration Requirements

Official labeling defines specific constraints to manage potential interactions. When oral Acetylcysteine is used alongside activated charcoal, a mandatory separation of administration is required to minimize binding interference and ensure adequate exposure. This timing rule is critical to the efficacy of Acetylcysteine in specific clinical scenarios. Furthermore, the restriction against direct mixing with certain antibiotics necessitates that these medicines must be administered separately to avoid the documented loss of antibiotic activity. Acetylcysteine may also cause a false-positive reaction when testing for urinary ketones using specific reagent dipsticks.

Advertisements

Mechanism of Action

How ACC (Acetylcysteine) Works

Acetylcysteine exerts its actions through distinct biochemical and molecular pathways, primarily leveraging its reactive sulfhydryl group.

Modulation of Redox Homeostasis

ACC acts as a precursor for the endogenous tripeptide glutathione (GSH) by supplying the rate-limiting substrate, L-cysteine. This action replenishes depleted cellular GSH stores, which are crucial for maintaining redox balance and cellular detoxification. Enhanced GSH availability promotes the cell's capacity to neutralize free radicals and reactive oxygen species, thereby modulating intracellular oxidative stress.

Direct Reduction of Disulfide Bonds

The free sulfhydryl group on Acetylcysteine functions as a reducing agent, engaging directly with mucoproteins to cleave their internal and inter-molecular disulfide bonds. This molecular modification decreases the degree of cross-linking and polymerization within secretions. The resulting structural consequence is a reduction in the viscosity of highly cross-linked secretions.

Support for Detoxification Cascades

ACC supports phase II detoxification pathways by directly supplying GSH for the conjugation of highly reactive, electrophilic metabolites, such as N-acetyl-p-benzoquinone imine (NAPQI). This conjugation and subsequent clearance of toxic intermediates prevents cellular macromolecular damage.

Advertisements

Dosage and Administration Information

The administration of Acetylcysteine is dependent on its use as either a mucolytic agent or as an antidote for acetaminophen toxicity, with distinct routes, dosages, and duration schedules utilized in clinical practice.


Administration Scope

Usage Context Route of Administration Dosing Schedule (Example Regimens)
Mucolytic Use Inhalation (Nebulization), Direct Instillation, or Oral Inhalation: Typically 3 to 5 mL of 20% solution, 3 to 4 times a day.
Antidote Use Intravenous (IV) Infusion or Oral IV: Total dose of 300 mg/kg body weight administered sequentially over 20 to 21 hours.
Oral: 140 mg/kg loading dose followed by 70 mg/kg maintenance doses every 4 hours for 17 total doses.

Preparation and Procedural Rules

Preparation requirements:

  • IV Solution: Must be diluted in compatible fluids, such as 5% Dextrose or 0.9% Sodium Chloride, before infusion.
  • Oral Forms: Effervescent tablets or powder packets require dissolution in water or a non-metallic liquid before consumption.

Age-group administration rules:

  • Pediatric Patients: IV regimens require specific fluid volume adjustments for patients weighing less than 40 kg to prevent fluid overload.

Missed-dose rules:

  • In the oral antidote regimen, any dose that is vomited within one hour of administration should be readministered immediately.

Connection to the overall use protocol: Clinical protocols divide Acetylcysteine's use into either a mandatory, multi-step fixed-duration protocol (for acute toxicological events) or an intermittent schedule (for supportive respiratory care). This distinction dictates the exact route, required dilution, and total treatment time.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for ACC (Acetylcysteine)

Evidence for Use as an Antidote in Acute Overdose

The use of Acetylcysteine as an antidote reflects foundational clinical observation and rigorous protocols designed for critical care. This evidence base consists of observational cohort studies and case series, rather than comparative trials, as the need for rapid intervention in acute overdose requires reliance on established management strategies. Research in this area was studied for measures related to preventing major liver injury and was evaluated in both adult and pediatric patients following acute toxic ingestions. These studies tracked critical measurements of liver function and overall patient outcomes.

Studies reported patterns related to changes in specific biomarkers linked to the liver’s protective processes. Regulatory protocols describe specific management goals and timeframes for administration. This evidence base is considered high-level due to the consistent findings reported over decades of use and its long-standing role in official regulatory protocols.

Evidence for Chronic Use in COPD and Chronic Bronchitis

For supportive use in respiratory conditions, the evidence comes from numerous Randomized Controlled Trials (RCTs), systematic reviews, and meta-analyses. Researchers examined the long-term use of the agent in adults with Chronic Obstructive Pulmonary Disease (COPD) and chronic bronchitis. These studies focused on outcomes related to physical discomfort and changes in daily functioning or activity level, with a primary focus on the frequency of exacerbations—acute or disruptive episodes where symptoms become more noticeable.

The findings varied across the numerous trials. Some large studies reported no observed difference in primary outcomes, such as the gradual decline in lung function measurements. However, other meta-analyses reported patterns related to measured differences in the frequency of exacerbations in certain patient groups, particularly those who were not taking inhaled steroids concurrently. This variability in reported outcomes means that evidence quality varies across studies. This indication is generally assigned a moderate level of certainty in research reviews.

What is Still Uncertain About the Research Evidence

The evidence highlights several important areas where certainty remains low. For chronic lung conditions, the findings varied, and the evidence quality varies across studies, particularly regarding the effect on lung function decline. For acute lung injury (ARDS) and Cystic Fibrosis, sample sizes were modest in many trials, and the follow-up durations were limited, contributing to low certainty. Long-term effects for many outcomes are not fully established, and there is continuing uncertainty regarding the patterns of outcomes observed in different patient groups when the agent is studied over extended periods.

Key Studies & References

  1. N-Acetylcysteine - StatPearls - NCBI Bookshelf (NIH)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about ACC (Acetylcysteine) (FAQ)


Q: Is ACC considered an over-the-counter medicine or a prescription?

According to official regulatory documents, Acetylcysteine is designated as a prescription medicine for its two primary approved uses: as an antidote for specific toxic ingestions and as an inhaled medicine for respiratory support. However, a similar form, N-acetylcysteine (NAC), is also widely available as a dietary supplement that is regulated under different guidelines.


Q: Is it normal to notice a change in the color or smell of my mucus while taking ACC?

Official information notes that the medicine itself may have a slight disagreeable odor, which some patients may initially notice. The color change explicitly mentioned in regulatory documents pertains to the solution of the medicine after the container is opened, which is a chemical reaction that does not affect its safety or effectiveness.


Q: Does ACC interact with common cold or flu medicines?

Official drug labels list specific drug-to-drug interactions for Acetylcysteine. These labels also include a general caution that the medicine may interact with other types of medications, including some over-the-counter products for cold and flu symptoms. This is why official drug labels include the requirement to inform a healthcare professional about all concurrent medicines.


Q: Are there any specific vitamins or supplements that shouldn't be taken with ACC?

Specific negative interactions with individual vitamins or supplements are not always detailed in regulatory documents. However, official safety profiles note the importance of providing a healthcare provider with a comprehensive list of all concurrent medications, vitamins, and herbal supplements to properly manage the overall safety profile.


Q: Can I take ACC if I am taking blood thinners?

Official regulatory documents indicate that co-administration with medicines that slow blood clotting (such as antiplatelet or anticoagulant drugs) is associated with an increased potential for bruising and bleeding.


Q: Are there specific food items or drinks that interact with ACC?

Official regulatory labels do not commonly list specific food-to-drug interactions for Acetylcysteine. However, patient safety materials advise discussing the use of the medicine with food, alcohol, or tobacco with a healthcare professional as part of a general safety review.


Q: What is the difference between a mucolytic and an expectorant?

Acetylcysteine is classified as a mucolytic agent because it works by chemically breaking down the internal structure of thick, sticky mucus. An expectorant works via a different mechanism, typically by promoting moisture in the airways to help thin and loosen secretions, making them easier to clear.


Q: Does ACC work better for a dry cough or a wet cough?

The medicine's mechanism of action, which is to reduce the viscosity of secretions, means it is indicated for conditions involving excessive or thick mucus. Official information suggests that Acetylcysteine is therefore indicated for wet, productive coughs and is typically not used for a dry cough.


Q: Why does the packaging mention something about the smell of sulfur?

Official drug labels and patient guides state that the medicine may naturally have a slight disagreeable odor, which is sometimes described as similar to sulfur. This characteristic smell is a known part of the medicine's composition and is officially documented as not affecting its safety or ability to work.


Q: Does ACC affect blood pressure or heart rate?

According to official safety information, the medicine is known to have properties that may lower blood pressure. For this reason, official sources document the need for close monitoring when it is used alongside other medications that lower blood pressure, due to the potential for blood pressure to drop too low.


Q: What does 'contraindicated' mean in relation to ACC use?

In official medical documentation, a contraindication is a strict safety statement indicating that the medicine is not suitable for use by a patient. For Acetylcysteine, this primarily applies to anyone with a known severe allergy or a history of anaphylactic reactions to the active substance or its components.


Q: Can taking ACC make me feel drowsy or affect my ability to drive?

Regulatory documents list drowsiness as a possible adverse effect. Due to the potential for this effect, activities requiring full alertness, such as driving or operating heavy machinery, may need to be approached with awareness of how the medicine affects the individual.


Q: Is there any official guidance on mixing ACC with juices or other liquids?

Official preparation instructions state that certain forms of the medicine should be dissolved in water or a non-metallic liquid. This specific instruction is given because Acetylcysteine is known to be physically incompatible with certain metals. The compatibility of specific liquids like fruit juices would need to be determined by a healthcare professional.


Q: Are there specific warning signs that mean I should stop taking ACC?

Official safety warnings highlight the potential for rare but serious reactions, such as severe, life-threatening skin conditions (like Stevens-Johnson syndrome) or anaphylactic shock. Signs of such severe reactions—including difficulty breathing, sudden swelling, or severe rash—are documented as requiring immediate medical attention.


Q: How is ACC eliminated from the body?

When taken, the medicine is rapidly processed in the body and is largely broken down into the amino acid cysteine. The final metabolic products, which are eliminated from the body, primarily include cysteine, glutathione, and inorganic sulfate.


Q: Do other countries use ACC for the same purposes as the US/Europe?

Acetylcysteine is used globally for its primary purposes as an antidote and a mucolytic agent. However, its regulatory classification can differ by region; some countries outside of the US and parts of Europe have approved the product as an over-the-counter medicine for respiratory support.


Q: Are there any long-term effects associated with using ACC?

Official research summaries note that for chronic respiratory use, studies have not yet fully established the long-term safety profile of the drug. However, when reviewing non-clinical safety data, official toxicology reports in animal studies have shown no evidence of oncogenic activity (cancer-causing potential).


Q: Can children use ACC, and is there a specific formulation for them?

The eligibility for children depends on the specific use; for general mucolytic use, it is typically allowed for adolescents over the age of 12 years. The medicine is manufactured into an oral solution form, which can be dissolved; however, official documents do not list a separate, specific pediatric-only formulation.


Q: How often do people usually need to take ACC for a standard course of treatment?

For its use as a mucolytic agent in respiratory support, regulatory documents describe intermittent administration schedules. A typical regimen for inhalation or oral use is often detailed as being administered three to four times a day.

Advertisements

How should ACC (Acetylcysteine) be stored and disposed of?

Storage Conditions

Classification Requirement
Labeled Temperature Store unopened product at Controlled Room Temperature (20 C to 25 C), with excursions permitted up to 30 C.
Container Protection Keep the product in the original package or outer carton to protect from moisture and light.
Container Incompatibility Acetylcysteine is not compatible with rubber or certain metals (e.g., iron, copper, nickel); plastic or glass containers are satisfactory.

Stability and Handling

The stability requirements vary once the product container is opened or the solution is prepared:

  • Opened Solution Vials: The unused portion of undiluted sterile solution must be stored in a refrigerator (2 C to 8 C) and discarded after 96 hours. This is due to the absence of an antimicrobial agent.
  • Diluted Forms: Dilutions for oral or inhalation use must be used within one hour. Solutions prepared for intravenous infusion must be started within 3 hours of dilution.
  • Child Protection: All forms of this medicine must be kept out of the sight and reach of children.

Disposal Requirements

Unused or expired Acetylcysteine must be handled as pharmaceutical waste and disposed of in accordance with local requirements. The medicine must not be thrown away via wastewater or household waste; consult a pharmacist for guidance on safe disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of ACC (Acetylcysteine) found in:

A-Z Index: